NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$1.61 USD
-0.08 (-4.73%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Income Statements
Fiscal Year end for NRx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 28 | 44 | 116 | 1 | 1 |
Income After Depreciation & Amortization | -28 | -44 | -116 | -1 | -1 |
Non-Operating Income | -2 | 5 | 23 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -40 | -93 | 0 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -40 | -93 | 0 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -40 | -93 | 0 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -44 | -116 | -1 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -28 | -44 | -116 | -1 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.58 | 6.58 | 4.69 | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.70 | -6.80 | -74.10 | NA | NA |
Diluted Net EPS (GAAP) | -4.00 | -6.00 | -74.40 | -1.60 | -1.10 |
Fiscal Year end for NRx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.05 | 6.00 | 4.40 | 5.80 | 8.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.05 | -6.00 | -4.40 | -5.80 | -8.19 |
Non-Operating Income | -0.85 | -0.30 | 0.15 | -0.21 | -0.53 |
Interest Expense | 0.00 | 0.23 | 0.08 | 0.04 | 0.00 |
Pretax Income | -7.90 | -6.53 | -4.33 | -6.06 | -8.72 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.90 | -6.53 | -4.33 | -6.06 | -8.72 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.90 | -6.53 | -4.33 | -6.06 | -8.72 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 10.52 | 8.85 | 7.58 | 8.20 | 7.32 |
Diluted EPS Before Non-Recurring Items | -0.75 | -0.74 | -0.50 | -0.70 | -1.20 |
Diluted Net EPS (GAAP) | -0.75 | -0.74 | -0.50 | -0.70 | -1.20 |